Quick Facts

Chemical Name
Growth Hormone Secretagogue
Also Known As
Ipamorelin Acetate, IPAM
Category
Growth Hormone
Administration
Typically administered via subcutaneous injection

What is Ipamorelin?

Ipamorelin is a pentapeptide growth hormone secretagogue that belongs to the ghrelin mimetic class. Developed by Novo Nordisk, it is considered one of the cleanest growth hormone releasing peptides due to its high selectivity. Unlike other GH secretagogues, ipamorelin does not significantly increase cortisol, prolactin, or ACTH levels, making it attractive for research applications where minimal side effects are desired. It stimulates the pituitary gland to release growth hormone in a pulsatile manner, mimicking the body's natural GH release patterns.

How Does Ipamorelin Work?

Ipamorelin works by binding to ghrelin receptors (GHSR) in the pituitary gland, stimulating the release of growth hormone. It also suppresses somatostatin, the hormone that inhibits GH release. The peptide's selectivity comes from its specific binding profile - it strongly activates GH release while having minimal effect on other pituitary hormones. This selectivity results in a cleaner hormone response compared to other GH secretagogues like GHRP-6 or hexarelin.

Research-Backed Benefits

Growth Hormone Release

Strong Evidence

Stimulates natural GH secretion in a pulsatile pattern similar to physiological release.

Improved Body Composition

Moderate Evidence

May support muscle mass gains and fat loss through elevated GH levels.

Enhanced Sleep Quality

Moderate Evidence

GH release during sleep may be enhanced, improving overall sleep quality and recovery.

Bone Density Support

Emerging Research

Elevated GH levels may contribute to improved bone mineral density over time.

Anti-Aging Properties

Emerging Research

May help address age-related decline in growth hormone levels.

Dosage Guidelines

Disclaimer: This content is for educational purposes only. Peptides are research compounds not approved by the FDA for human use. Always consult with a qualified healthcare provider.

Typical Range
100-300 mcg per dose
Frequency
2-3 times daily
Duration
8-16 weeks in research protocols

Often used in combination with a GHRH peptide like CJC-1295 for synergistic effects.

Side Effects & Safety

  • Transient head rush or dizziness
  • Increased hunger in some individuals
  • Water retention possible
  • Tingling or numbness (rare)

Frequently Asked Questions

Ipamorelin stimulates growth hormone release, which may support muscle growth, fat loss, improved sleep, bone density, and recovery.
Ipamorelin stimulates your body to produce its own growth hormone naturally, while HGH is exogenous hormone. This results in more physiological GH patterns.
Research protocols often use Ipamorelin before bed and/or in the morning on an empty stomach for optimal GH release.
Yes, it's commonly combined with GHRH peptides like CJC-1295 for synergistic effects on GH release.
Initial effects on sleep quality may be noticed within 1-2 weeks. Body composition changes typically require 8-12 weeks.

References

  1. Raun K, et al. "Ipamorelin, a new growth hormone secretagogue." European Journal of Endocrinology, 1998. PMID: 9758455
  2. Smith RG, et al. "Effects of growth hormone secretagogues." Endocrine Reviews, 2005. PMID: 15632316

Get the Complete Ipamorelin Research Protocol

Join 50,000+ researchers with instant access to our comprehensive peptide resource.

Continue Your Research